Pediatric Bone Marrow Failure: A Broad Landscape in Need of Personalized Management

Area of Science:

• Pediatric Hematology
• Oncology
• Genetics

Background:

• Severe bone marrow failure (BMF) in children is life-threatening, often caused by inherited bone marrow failure syndromes (IBMFSs) or malignant diseases like myelodysplastic syndrome (MDS) and aplastic anemia (AA).
• Effective treatment is crucial to prevent complications like infections and bleeding, thereby improving overall survival (OS).

Purpose of the Study:

• To review current clinical management strategies for pediatric BMF.
• To discuss hematopoietic stem cell transplantation (HSCT) and alternative therapies.
• To explore the potential of gene therapy for inherited BMF.

Main Methods:

• Literature review of current clinical practices for pediatric BMF.
• Analysis of treatment outcomes for HSCT using matched sibling donors (MSD), matched unrelated donors (MUD), and alternative donors with post-transplantation cyclophosphamide (PT-Cy).
• Evaluation of emerging gene therapy approaches for IBMFSs.

Main Results:

• Allogeneic HSCT achieves 60-90% OS for BMF, with similar rates for alternative donors using PT-Cy.
• HSCT effectively restores hematopoiesis but carries significant risks, making it not always the first-line therapy.
• Gene therapy shows promise for IBMFSs but is still in early developmental stages.

Conclusions:

• HSCT is a curative option for pediatric BMF, with improving outcomes across donor types.
• Disease-specific treatments and emerging gene therapies are vital considerations for managing pediatric BMF.
• Further research into gene therapy is needed to overcome HSCT limitations for inherited BMF.